Welcome!
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.
We realize an active ongoing discussion always surrounds Clinical Trials - What are they, who runs them, how do you become a part of one.
We are excited to share that we have partnered with EmergingMed.com to provide to you the EmergingMed Clinical Trial Navigation Service. EmergingMed.com's clinical trial database includes all treatment trials from clinicaltrials.gov along with updates reported to them directly by trial sponsors and sites. Clicking through our informational webpage to their search allows you to fill out a short questionnaire to identify clinical trials looking for your specific diagnosis, stage and treatment history. Their database includes the full national database of cancer treatment trials from all sponsors. You can also access our Clinical Trial page by the dropdown in our navigation bar, above, under FIGHT.
A clinical trial or study (sometimes called interventional studies) involves research using people who volunteer to participate that adds to the medical knowledge about that study. In a clinical trial, volunteers receive specific interventions according to a protocol created by the investigators for that trial. Interventions can be medical products (drugs or devices), procedures, or changes to a participants behavior. Outcomes are measured to determine safety and effectiveness. Clinical trials have standards or eligibility criteria outlining who can participate, and all clinical studies are led by a principal investigator, most often a medical doctor.
It is important that the participant's usual health care provider work with the research team so participants can make sure that the study protocol will not conflict with other medications or treatments being received.
We would love to hear your feedback and discussions on clinical trials -- your frustrations and triumphs. Join us in our patient forums to discuss! Click 'Ask a Question' or go to the Forums Page to read what our community has to say!
Please feel free to offer comments and raise questions in our
discussion forums.
Bispecifics, or bispecific antibodies, are advanced immunotherapy drugs engineered to have two binding sites, allowing them to latch onto two different targets simultaneously, like a cancer cell and a T-cell, effectively...
The prefix “oligo–” means few. Oligometastatic (at diagnosis) Oligoprogression (during treatment)
There will be a discussion, “Studies in Oligometastatic NSCLC: Current Data and Definitions,” which will focus on what we...
Radiation therapy is primarily a localized treatment, meaning it precisely targets a specific tumor or area of the body, unlike systemic treatments (like chemotherapy) that affect the whole body.
The...
Biomarkers are genetic mutations (like EGFR, ALK, KRAS, BRAF) or protein levels (like PD-L1) in tumor cells that help guide personalized treatment, especially NSCLC, directing patients to targeted therapies or immunotherapies...
Hi Stan! So good to hear from you. I'm sorry for the late response. I too have been out of town with family and missed your post, probably because I was...
It is so good to hear from you! And I am so happy to hear that your holidays have been good and that you are doing well. It sounds like your...
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.
An antibody–drug conjugate (ADC) works a bit like a Trojan horse. It has three main components: